Tofacitinib
also Xeljanz
Tofacitinib, sold under the brand Xeljanz among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, polyarticular-course juvenile idiopathic arthritis, and ulcerative colitis. It is a janus kinase (JAK) inhibitor, discovered and developed by the National Institutes of Health and Pfizer.
Read “Tofacitinib” on Wikipedia and its adverse effects · text from Wikipedia, CC BY-SA 4.0
Information, not medical advice. Talk to a licensed doctor or pharmacist before starting or changing a treatment.
Research 10
- Pattern hair loss distribution: a novel presentation for alopecia areata
- Efficacy, safety, and Pharmacoeconomics of Three Common Strategies for Pediatric Alopecia Areata Patients: A Retrospective Cohort Study
- Selective Delivery of Tofacitinib Citrate to Hair Follicles Using Lipid-Coated Calcium Carbonate Nanocarrier Controls Chemotherapy-Induced Alopecia Areata
- Efficacy and Safety of Tofacitinib in Lichen Planopilaris: A Retrospective Series of 74 Patients
- Hair Loss in Lichen Planopilaris and Frontal Fibrosing Alopecia: Not Always Irreversible
- Efficacy and Safety of Topical Tofacitinib for the Treatment of Alopecia Areata
- A Practical Approach to the Diagnosis and Management of Hair Loss in Children and Adolescents
- Safety and efficacy of tofacitinib in 97 alopecia areata patients
- 66-Year-Old Female with Itchy Scalp and Hair Loss
- Tofacitinib therapy for children with severe alopecia areata
Community 6
- Xeljanz medication for alopecia universalis?
- Topical solution recommendation
- Topical solution recommendation
- IGE Hair Loss and Miniaturization
- Anyone with LPP have regrowth with Xeljanz?
- Alopecia Areata Question